Design Therapeutics, Inc. announced that preclinical data for the company's novel GeneTAC(TM) small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orleans from April 23-27, 2023. FECD is characterized by progressive corneal degeneration leading to vision loss and affects millions of people in the U.S. Approximately 75% of cases are caused by a mutation in the transcription factor 4 (TCF4) gene, consisting of a CTG trinucleotide repeat expansion that leads to the formation of pathogenic RNA foci in the nucleus and the mis-splicing of multiple transcripts. There are no disease-modifying therapies approved for FECD, and advanced cases generally require ophthalmology, including corneal transplant.

DT-168 is designed to selectively target the expanded CTG repeats in the TCF4 gene to reduce RNA foci formation and mis-splicing. In preclinical studies, DT-168 reduced foci in patient-derived primary corneal endothelial cells (CECs) to levels seen in cells from healthy individuals with low nanomolar IC50 values. Treatment with DT-168 also significantly improved mis-splicing in patient-derived CECs across a panel of genes.

Design's anticipated timeline to submit an IND for DT-168 in the second half of 2023; the potential of Design's GeneTAC(TM) Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023. The treatment with DT-168 also significantly Improved mis- Splicing in patient-derived Cecs across a panel of geneTAC(TM) molecules.